Jacob Bell is a Senior Reporter for BioPharma Dive, with previous experience at TheStreet, Education Week, and McClatchy DC. Jacob's reporting focuses on the pharmaceutical and biotechnology industries, covering topics such as drug development, regulatory updates, and industry trends. His work has also been featured in GeeksULTD.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jacob Bell's coverage is heavily focused on the healthcare and pharmaceutical industries, with particular attention to biotechnology. His articles often incorporate press releases and data citations, indicating a preference for factual and industry-specific information.
Given his focus on private sector announcements, Jacob may be interested in pitches related to new product launches, significant investments or acquisitions within the healthcare and biotech sectors. Furthermore, he might be open to expert commentary from professionals well-versed in various aspects of biotechnology, pharmaceuticals, neurological diseases such as ALS research or gene therapy.
As there is no specific geographic focus mentioned for Jacob's coverage area, it would be beneficial to provide globally relevant insights pertaining to the topics covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
At the center of a new licensing deal is an experimental medicine currently being tested in a roughly 250-person study that should produce results next year.
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
The collaboration is another vote of confidence in Dewpoint's biomolecular condensates research, which had already attracted interest from the likes of Bayer and Novo Nordisk.
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
By: Jacob Bell
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an “accelerated approval” application.
By: Jacob Bell
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that deny coverage of Qalsody because it’s “experimental and investigational.”
By: Jacob Bell
“Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The company plans to use its new funds to get to “proof of concept” for its medicines.
By: Jacob Bell
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.
Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the drug, which it’s been developing with Prothena for more than a decade.
(833) 317-6278 
